The Chinese drug administration included Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) serplulimab injection in combination with chemotherapy for gastric cancer in the regulator's breakthrough therapy drug program, according to a Shanghai bourse filing on Friday.

A drug included in the program will accelerate its review and approval process for its designated indication.

The pharmaceutical company's subsidiary, Shanghai Henlius Biotech, developed the drug, which is also used as a treatment for lung cancer.

Fosun's Hong Kong shares slumped less than 4% and Shanghai shares fell over 1% during the morning trade.